13F Holdings
中文EN

SBFM Sunshine Biopharma Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1402328 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-5.2%
TTM net income YoY-3.0%
TTM EPS YoY—
Revenue 3-yr CAGR20.2%
Net income 3-yr CAGR—

Margins

Gross margin30.4%
Operating margin-17.2%
Net margin-17.5%
FCF margin—
EBITDA margin-16.3%

Returns

ROE-23.4%
ROA-18.9%
ROIC (approx.)-33.3%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets15.4%
Debt / equity0.00x
Current ratio6.47x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$36.31M$34.87M$24.09M$4.35M$228,426
Cost of revenue$24.05M$24.20M$15.75M$2.65M$117,830
Gross profit$12.26M$10.67M$8.34M$1.70M$110,596
R&D expense$604,308$933,902$1.86M$811,858$672,209
SG&A expense$18.48M$16.48M$13.12M$28.70M$2.55M
Operating income-$6.23M-$5.81M-$4.79M-$27.00M-$2.44M
Interest expense$0$8,774$137,308$39,412$328,818
Pretax income-$5.95M-$5.37M-$4.11M-$26.51M-$12.44M
Income tax$21,609-$234,858$395,166$233,304$0
Net income-$5.98M-$5.13M-$4.51M-$26.74M-$12.44M
EBITDA-$5.89M-$5.59M-$4.64M-$26.98M-$2.43M
EPS (basic)-1.44-7.32-351.36-1.76-4.76
EPS (diluted)—-7.32-351.36-1.76-4.76
Weighted avg. shares (diluted)—701,74912,82515.18M2.61M
Balance sheet
Cash & equivalents$9.12M$9.69M$16.29M$21.83M$2.05M
Receivables$3.46M$3.87M$2.55M$1.91M$7,798
Inventory$13.47M$11.28M$5.73M$3.29M$105,650
Current assets$26.85M$25.97M$24.89M$27.31M$2.20M
PP&E, net$557,370$546,055$365,868$394,249$7,061
Goodwill—$0$0$0$0
Intangibles$1.89M$3.02M$1.44M$776,856$0
Total assets$30.08M$30.56M$27.35M$29.24M$2.20M
Current liabilities$6.44M$6.31M$5.55M$6.93M$91,229
Total liabilities$7.04M$7.06M$6.14M$7.62M$1.99M
Shareholders' equity$23.04M$23.50M$21.21M$21.63M$211,662
Shares outstanding24,5302.58M14,01222.59M2.59M
Cash flow statement
Operating cash flow-$5.33M-$12.52M-$8.78M-$5.25M-$1.83M
Capital expenditure$174,491$1.66M$82,251$193,982$0
Free cash flow-$5.51M-$14.18M-$8.86M-$5.44M-$1.83M
Investing cash flow-$836,306-$1.98M-$656,150-$14.62M$0
Financing cash flow$4.75M$8.94M$3.43M$39.47M$2.90M
Depreciation & amortization$332,070$223,527$149,147$25,163$12,741
Share buybacks$0$3.14M$541,143——

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.